Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
Dose-adapted single-isocenter SRS for 4 to 10 brain mets (prospective): 22/40 outlived DS-GPA prediction, 1-yr local failure 5%, no G3-5 toxicity.
A CNS-only day on linac single-isocenter SRS for multiple brain mets. The one prospective cohort shows 1-yr local failure 5% with no G3-5 toxicity. Four planning or retrospective studies favor HyperArc and non-coplanar VMAT on gradient and V12Gy, and a simulated 1 mm GTV-PTV margin restored coverage lost to residual setup error.
read the full digest →Studies · 241
- Manual to automated (HyperArc) VMAT SRS transitionPaddick GI 5.42 vs 7.09 (P<.001), time in room 10.5 vs 11.4 min, RTOG CI unchanged; HyperArc 1-yr LC 90.1% across 377 mets.
- Dose-adapted single-isocenter SRS for 4 to 10 brain mets (prospective)mOS 8.1 mo, 1-yr OS 35.7%; 22/40 outlived DS-GPA prediction (≥17 needed for non-inferiority), 1-yr local failure 5%, no G3-5 toxicity.
- Interinstitutional plan quality: Elements MME vs RapidArc single-isocenter SRSRapidArc lowered median V12Gy 19.2 vs 23.7 cc (P<.0001) and improved conformity; MME lowered V5Gy and mean brain dose (2.57 vs 2.76 Gy).
- Automated single-isocenter SRS for multiple brain mets: outcomes and margins1y LC 89% per pt and 94% per lesion. Residual setup error caused coverage loss (V95 <95%) in 28 targets; simulated 1 mm GTV-PTV margin restored coverage.
- DCAT vs CoVMAT vs NcVMAT for single brain metNon-coplanar VMAT cut normal-brain V12Gy to 9.4 vs 11.6 (DCAT) vs 15.1 cm3 (coplanar VMAT) for 2-3 cm single brain mets, 20 Gy/1 fx.
- UK practice survey of NMSC radiotherapyOf 63 UK respondents, most chose one of four daily schedules (18-20 Gy/1#, 35 Gy/5#, 45 Gy/10#, 55 Gy/20#). Non-standard schedules varied widely, with 24 different regimens proposed.
- Radiotherapy for epithelial skin cancer (Locke)Local control 89% overall (93% untreated vs 80% recurrent) across 531 BCC/SCC lesions; dose/fx <2 Gy predicted local failure (p=0.01).
- Hypofractionated electron beam RT for epithelial skin cancer, 434 cases3-yr actuarial LRF 97.5% (54 Gy/18fx) vs 96.1% (44 Gy/10fx) with electrons for BCC/SCC; no significant difference in either histology.
- Predictors of recurrence after RT for NMSCRecurrence 15.8% at median 18.4 mo across 448 RT-treated NMSCs; age, size ≥2 cm, immunosuppression and photon modality independently predicted recurrence.
- Volume threshold of brain metastases for Linac-based SRSIn a GK-vs-VMAT replanning study, GK beat VMAT on plan quality for targets ≤0.4 cc, while VMAT won for targets >0.4 cc.
- ADT Class and Cardiovascular Risk (Hahn, ASCO GU 2026)MACE ~four per 100 person-yrs overall; ~37% numerically lower with GnRH antagonist vs agonist; 11 per 100 person-yrs with preexisting CVD.
- RT for nasal skin SCC, Princess Margaret experienceLocal relapse-free rate 90% at 2y and 85% at 5y, CSS 96%, no RTOG G4 late toxicity in 94 pts treated with mostly orthovoltage RT.